Additionally, in SOLTI-1007 NeoEribulin trial14, an increase of CelTIL after 1 cycle of eribulin monotherapy (i.e., at cycle 2 day 1) was significantly associated with residual cancer burden 0 or 1 (RCB-0/1) at surgery after the completion of 4 cycles in patients with HER2-negative breast cancer (Supplementary Fig. 2a, b). This evidence concerns the gene ERBB2 and breast cancer.